Cargando…
Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease
Mitochondrial dysfunction is thought to contribute to neurodegeneration in Parkinson’s disease (PD), yet the cellular events that lead to mitochondrial disruption remain unclear. Post-mortem studies of PD patient brains and the use of complex I inhibitors to model the disease previously suggested a...
Autores principales: | Mor, Danielle E., Murphy, Coleen T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653964/ https://www.ncbi.nlm.nih.gov/pubmed/33178902 http://dx.doi.org/10.1016/j.tma.2020.07.007 |
Ejemplares similares
-
Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria
por: Mor, Danielle E., et al.
Publicado: (2020) -
High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
por: Sohrabi, Salman, et al.
Publicado: (2021) -
GAIT-GM integrative cross-omics analyses reveal cholinergic defects in a C. elegans model of Parkinson’s disease
por: McIntyre, Lauren M., et al.
Publicado: (2022) -
Mitochondrial dysfunction-targeting therapeutics of natural products in Parkinson’s disease
por: He, Ting, et al.
Publicado: (2023) -
Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease
por: Tapias, Victor, et al.
Publicado: (2023)